Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

Jefferies Healthcare Conference Presentation – June 2019

ObsEva Investor Presentation – April 2019

ObsEva Short Report 2018

1 3 4 5

Press Releases

ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

press release

January 6, 2022

–Once daily linzagolix 200mg with ABTmet both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo…

Read more

ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

press release

January 3, 2022

GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…

Read more

ObsEva Added to the NASDAQ Biotechnology Index

press release

December 20, 2021

GENEVA, Switzerland December 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…

Read more
1 2 3 70

General Meetings

ObsEva Extraordinary General Meeting 2018

January 28, 2018

Read more

ObsEva Annual General Meeting 2017

June 13, 2017

Read more
1 2 3

Upcoming Events

Sorry, there are no events available yes.

 

Contacts

ObsEva Switzerland Office

Chemin des Aulx,12

1228, Plan-Les-Ouates, Geneva, Switzerland

+41 (0)22 552 3840


contact@obseva.ch

Media

Shauna Dillon

+41 (0)22 552 1550 Office

+41 79 360 3533 Mobile

shauna.dillon@obseva.ch

Investor relations


.


Joyce Allaire

+1 (617)-435-6602

ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

    * Type:


    InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue